亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma

医学 杜瓦卢马布 肝细胞癌 临床终点 实体瘤疗效评价标准 内科学 不利影响 中性粒细胞减少症 进行性疾病 胃肠病学 临床研究阶段 癌症 外科 随机对照试验 化疗 免疫疗法 无容量
作者
Yun Bin Lee,Joon Yeul Nam,Eun Ju Cho,Jeong‐Hoon Lee,Su Jong Yu,Hyo‐Cheol Kim,Jin Chul Paeng,Jung‐Hwan Yoon,Yoon Jun Kim
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:29 (18): 3650-3658 被引量:61
标识
DOI:10.1158/1078-0432.ccr-23-0581
摘要

PURPOSE: Synergistic effect of radiotherapy and immunotherapy for the treatment of hepatocellular carcinoma (HCC) has been reported. This phase I/IIa pilot trial evaluated preliminary efficacy and safety of combination of radioembolization with yttrium-90 microspheres (Y90-radioembolization) and durvalumab in patients with locally advanced unresectable HCC. PATIENTS AND METHODS: Patients with Child-Pugh score ≤ 7 and locally advanced HCC, defined as Barcelona Clinic Liver Cancer (BCLC) stage B HCC or BCLC-C disease without extrahepatic metastases, received Y90-radioembolization followed by intravenous durvalumab 1,500 mg 7 to 14 days after Y90-radioembolization and every 4 weeks thereafter. Primary endpoint was time to progression (TTP) assessed by modified RECIST (mRECIST). Secondary endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR) determined by mRECIST, and safety. RESULTS: All 24 patients enrolled received Y90-radioembolization and 23 received at least one dose of durvalumab. Median follow-up duration was 19.0 months (range, 2.2-24.2). Median TTP was 15.2 months [95% confidence interval (CI), 6.1-not estimated]. Median OS was not reached and 18-month OS rate was 58.3% (95% CI, 36.4-75.0). Median PFS was 6.9 months (95% CI, 5.4-15.2). Seven (29.2%) patients had a complete response and 13 (54.2%) had a partial response; ORR was 83.3% (95% CI, 62.6-95.3). Eleven (47.8%) patients experienced any-grade treatment-related adverse events. Two (8.7%) patients had grade 3 treatment-related adverse events (neutropenia and fever). None experienced any treatment-related serious adverse events. CONCLUSIONS: In patients with locally advanced unresectable HCC, the combination of Y90-radioembolization and durvalumab demonstrated promising efficacy and safety, warranting further evaluation in large-scale controlled trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
8秒前
如意嘉熙完成签到,获得积分10
17秒前
32秒前
玩命的紫夏完成签到,获得积分10
52秒前
55秒前
1分钟前
1分钟前
英姑的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
CJF完成签到,获得积分10
1分钟前
hyhy完成签到,获得积分10
1分钟前
清脆鸡翅完成签到 ,获得积分10
1分钟前
狂野羿完成签到,获得积分10
1分钟前
KON完成签到,获得积分10
1分钟前
清脆鸡翅关注了科研通微信公众号
1分钟前
老迟到的机器猫完成签到,获得积分10
1分钟前
孝顺的冰姬完成签到,获得积分10
1分钟前
2分钟前
缓慢不正完成签到,获得积分10
2分钟前
阔达的芹菜完成签到,获得积分10
2分钟前
xin完成签到,获得积分10
2分钟前
机智笑南完成签到,获得积分10
3分钟前
情怀的应助被GIA采纳,获得10
3分钟前
狂野狂野人完成签到 ,获得积分10
3分钟前
我是老大的应助被小小昌采纳,获得10
3分钟前
3分钟前
孤独难胜完成签到,获得积分10
3分钟前
mengdewen发布了新的文献求助10
3分钟前
mengdewen完成签到,获得积分10
3分钟前
含蓄的亦旋完成签到,获得积分10
3分钟前
乐乐完成签到 ,获得积分20
3分钟前
温暖无招完成签到 ,获得积分10
4分钟前
4分钟前
GIA发布了新的文献求助10
4分钟前
sherrydj完成签到,获得积分10
4分钟前
4分钟前
4分钟前
4分钟前
小小昌发布了新的文献求助10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179924
求助须知:如何正确求助?哪些是违规求助? 9570159
关于积分的说明 21808379
捐赠科研通 7775767
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478918